Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone. RESEARCH DESIGN AND METHODS: In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide was administered once daily at any time of the day. Lixisenatide was administered once daily within 1 h prior to the morning or evening meal. RESULTS: At week 26, liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference −0.62% [95% CI −0.8; −0.4]; P < 0.0001), with more patients reaching HbA1c <7% (53 mmol/mol) and ≤6.5% (48 mmol/mol) versus lixisenatide (74.2% and 54.6% for liraglutide vs. 45.5% and 26.2% for lixisenatide; P < 0.0001 for both). Liraglutide reduced fasting plasma glucose more than lixisenatide (estimated treatment difference −1.15 mmol/L [95% CI −1.5; −0.8]; P < 0.0001). Liraglutide provided greater reduction in mean 9-point self-measured plasma glucose (P < 0.0001). However, postprandial glucose increments were smaller with lixisenatide for the meal directly after injection compared with liraglutide (P < 0.05), with no differences between treatments across all meals. Both drugs promoted similar body weight decrease (−4.3 kg for liraglutide, −3.7 kg for lixisenatide; P = 0.23). The most common adverse events in both groups were gastrointestinal disorders. Greater increases in pulse, lipase, and amylase were observed with liraglutide. Hypoglycemic episodes were rare and similar between the two treatments. CONCLUSIONS: At the dose levels studied, liraglutide was more effective than lixisenatide as add-on to metformin in improving glycemic control. Body weight reductions were similar. Both treatments were well tolerated, with low risk of hypoglycemia and similar gastrointestinal adverse event profiles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, liraglutide decreased HbA1C more significantly than lixisenatide (−1.8% vs. −1.2%) (Table 1).27”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [27]
In the citing paper
“Compared with EX, the frequency of subcutaneous injection of LIXI is less, and the incidence of gastrointestinal adverse reactions and hypoglycemia is lower. Compared with LIXI, LIR is more effective in improving blood glucose and reducing weight, and both treatments are well tolerated (75, 77, 78).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [75]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“secretion, inhibits gastric emptying, and reduces appetite and food intake (1).”
BackgroundSelf-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 2×
“the Study of Diabetes position statement underlines the importance of individualization of treatment targets and strategies (2).”
BackgroundSelf-citationAbraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“(ELIXA) (34) recently confirmed the cardiovascular safety of lixisenatide (35), results from the liraglutideCVOT Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) are”
BackgroundAndrea, D., Kakuk, P., & Judit, S. (2014) · University of Debrecen Electronic Archive (University of Debrecen) · Cited by 1,954
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 10×
“Similar to other GLP-1 RAs, the risk of hypoglycemia is low except when lixisenatide is used in combination with an SU or a basal insulin (7).”
BackgroundInfluentialDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Self-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Cited by
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“All data are from clinical trials reporting head-to-head comp vs liraglutide [37], lixisenatide vs liraglutide [38], exenatide once-weekly vs liraglutide [39], vs dulaglutide [42], and oral semaglutide vs liraglutide [43]) on a background of oral glucos equations to calculate common means and their standard deviations.”
MethodSelf-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Self-citationGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
“23), as were blood pressure reductions, although greater increases in pulse rate, amylase, and lipase were seen with liraglutide compared with lixisenatide.(51) In the GETGOAL-X open-label trial comparing once-daily lixisenatide to twice-daily exenatide over 24 weeks, A1c reductions were noninferior between the two (−…”
ResultGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Cornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Self-citationMaiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 125
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 117
Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 125
Self-citationGLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 103
Silver, H. J., Olson, D., Mayfield, D., Wright, P., Nian, H., Mashayekhi, M., Koethe, J. R., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15113 · Cited by 94
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 84
Huthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91
Self-citationOstawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0180-0 · Cited by 86
Dicembrini, I., Nreu, B., Scatena, A., Andreozzi, F., Sesti, G., Mannucci, E., & Monami, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1031-9 · Cited by 92
Cheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00962-3 · Cited by 81
Self-citationSwitching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65
Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 70
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
Sachinidis, A., Nikolic, D., Stoian, A. P., Papanas, N., Tarar, O., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Self-citationGiglio, R. V., Nikolić, D., Volti, G. L., Stoian, A. P., Banerjee, Y., Magán‐Fernández, A., Castellino, G., Patti, A. M., Chianetta, R., Castracani, C. C., et al. (2020) · Metabolites · doi:10.3390/metabo10100391 · Cited by 55
Self-citationDalsgaard, N. B., Vilsbøll, T., & Knop, F. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13128 · Cited by 54
Investigational insulin secretagogues for type 2 diabetes
Scheen, A. J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1152260 · Cited by 53
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Carlsson Petri, K. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0458-5 · Cited by 47
Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 44
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & De Jonghe, B. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
Frias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13764 · Cited by 46
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Perreault, L., Rodbard, H. W., Valentine, V., & Johnson, E. L. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0868-9 · Cited by 49
Matza, L. S., Boye, K. S., Stewart, K. D., Coyne, K. S., Wullenweber, P. K., Cutts, K. N., Jordan, J. B., Wang, Q., Yu, M., Currie, B. M., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13902 · Cited by 46
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0424-2 · Cited by 45
Del Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43
Nuhoho, S., Gupta, J., Hansen, B. B., Fletcher-Louis, M., Dang-Tan, T., & Paine, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00706-y · Cited by 41
Yoshiji, S., Minamino, H., Tanaka, D., Yamane, S., Harada, N., & Inagaki, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14666 · Cited by 40
“0 kg, respectively, considering that liraglutide was compared head-to-head with all the other GLP-1 RAs.(22-28) Using the following Equations (1) and (2), we normalized the HbA1c and body weight reduction of each GLP-1 RA against those of liraglutide by taking the ratio of their % HbA1c reduction and % body weight red…”
MethodClemens, K. K., Ernst, J., Khan, T., Reichert, S., Khan, M. Q., LaPier, H., Chiu, M., Stranges, S., Sahi, G., Castrillon-Ramirez, F., et al. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.023 · Cited by 40
Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39
Self-citationCardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Bailey, T. S., Takács, R., Tinahones, F. J., Rao, P. V., Tsoukas, G. M., Thomsen, A. B., Kaltoft, M. S., & Maislos, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12736 · Cited by 34
Valentine, V., Goldman, J. D., & Shubrook, J. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0287-y · Cited by 37
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“While both Lixisenatide and Liraglutide are well-tolerated, the former is superior at lowering weight and improving blood glucose levels [248 – 251].”
Jordy, A. B., Albayaty, M., Breitschaft, A., Anderson, T. W., Christiansen, E., Houshmand-Øregaard, A., Manigandan, E., & Bækdal, T. A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00976-x · Cited by 27
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management
McCarty, D., Coleman, M., & Boland, C. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017689878 · Cited by 27
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Cai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 28
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Hunt, B., Kragh, N., McConnachie, C. C., Valentine, W. J., Rossi, M. C., & Montagnoli, R. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.354 · Cited by 24
Feher, M., Vega-Hernandez, G., Mocevic, E., Buysse, B., Myland, M., Power, G. S., Nystrup Husemoen, L. L., Kim, J., & Witte, D. R. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0241-z · Cited by 23
Davies, M. J., Bianchi, C., & Del Prato, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 23
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Austin, G. O., & Tomás, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170181 · Cited by 25
Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Hunt, B., Ye, Q., Valentine, W. J., & Ashley, D. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0219-2 · Cited by 22
Hunt, B., Vega-Hernandez, G., Valentine, W. J., & Kragh, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12890 · Cited by 22
Gill, L. A., & Mackey, S. (2021) · Journal of Women s Health · doi:10.1089/jwh.2020.8683 · Cited by 22
Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)
Park, E. J., Lim, S. M., Lee, K. C., & Na, D. H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1192130 · Cited by 22
Trujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 22
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Van, J. T., Frías, J. P., Bonora, E., Raha, S., Meyer, J., Jung, H., Cox, D., Кониг, М., Peleshok, J. C., & Bethel, M. A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01140-9 · Cited by 20
Mezquita‐Raya, P., de Arellano, A. R., Kragh, N., Vega-Hernandez, G., Pöhlmann, J., Valentine, W. J., & Hunt, B. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0239-6 · Cited by 19
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 20
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
Tan, X., Cao, X., Zhou, M., Zou, P., & Hu, J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1360274 · Cited by 18
Ericsson, Å., Glah, D. R., Lorenzi, M. F., Jansen, J. P., & Fridhammar, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191953 · Cited by 23
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 18
Doggrell, S. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1441286 · Cited by 21
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
Demmel, V., Sandberg-Schaal, A., Jacobsen, J. B., Golor, G., Pettersson, J., & Flint, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0442-0 · Cited by 16
Wegeberg, A., Meldgaard, T., Bæk, A., Drewes, A. M., Vyberg, M., Jessen, N., Brock, B., & Brock, C. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13575 · Cited by 16
Xia, Y., Gao, Z., Hao, Z., Ma, H., Duan, K., & Yang, C. (2023) · Medicine · doi:10.1097/md.0000000000035739 · Cited by 17
Hunt, B., McConnachie, C. C., Gamble, C. L., & Dang‐Tan, T. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1347793 · Cited by 16
Kumar, N., & D’Alessio, D. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac276 · Cited by 14
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Hayek, A. A., & Dawish, M. A. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02053-0 · Cited by 15
Aroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
George, C. M., Byun, A., & Howard-Thompson, A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.05.043 · Cited by 13
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Richardson, K. M., Schembre, S. M., Jospe, M. R., Widmer, A., & Silver, H. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16395 · Cited by 13
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
Metadata
- Authors
- Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B.
- Affiliations
- St. Josef-Hospital (DE)
- University of Palermo (IT)
- Southmead Hospital (GB)
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Centre Hospitalier Universitaire de Nantes (FR)
- Corresponding author
- Nauck, Michael
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-16
- Volume
- 39
- Issue
- 9
- Pages
- 1501-1509
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2443999297
- Cited by
- 143
- References
- 38
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 19 · 2018: 19 · 2017: 31 · 2016: 9
- FWCI
- 26.13
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (other-oa)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, lixisenatide, metformin add-on therapy, glycemic control, HbA1c, fasting blood glucose, postprandial blood glucose, weight loss, gastrointestinal adverse effects, hypoglycemia, incretin-based therapy, GLP-1 receptor agonists
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Liraglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Treatment Outcome, Postprandial Period, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.